COVID-19

A “classic” vaccine | The European regulator launches a review of the Valneva vaccine

(The Hague) The European Medicines Agency (EMA) announced this Thursday the launch of the accelerated review of the anti-COVID-19 vaccine by the French-Austrian laboratory Valneva, which uses more conventional technology than the vaccines authorized so far within of the EU.

In clinical trials, it has been shown in clinical trials that the ‘virus-inactivated’ vaccine, an older technology than that used by the vaccines authorized so far in the EU, triggers “the production of antibodies directed against SARS-CoV-2 […] and it can help protect against disease, ”the Amsterdam-based EMA said in a statement.

Most flu vaccines and many childhood vaccines use this “inactivated virus” technology, and health officials hope that Valneva’s vaccine can reduce skepticism about COVID-19 vaccines that use HIV and other technologies. Recent

So far, only four vaccines, of two different types – and different from Valneva’s -, have been authorized by the EMA.

Reassuring technology for some

Pfizer and Moderna are messenger RNA vaccines, an innovative technology that injects chains of genetic instructions into the body that tell a patient’s cells what to do to fight disease.

AstraZeneca and Johnson & Johnson, for their part, use an innovative viral vector technology: they take as a carrier a very common type of virus called adenovirus, which has been modified to carry genetic information in the body to fight COVID-19.

Valneva’s vaccine “contains inactivated (killed) SARS-CoV-2, which cannot cause disease,” the EMA explained. When a person receives the vaccine, their immune system identifies the inactivated virus as foreign and produces antibodies against it.

“The EMA will evaluate the data as it becomes available to decide whether the benefits (of the Valneva vaccine) outweigh the risks,” the European agency said again, specifying that it could not yet estimate when an authorization decision could be made.

Vaccines typically take a few months to transition from review to authorization, although some, such as those developed in Russia and China, have been waiting longer.

The European Commission announced on November 10 that it had reached an agreement with Valneva for up to 60 million doses of the coronavirus vaccine by 2023.

The deal was good news for the company, which was shaken in September when the British government terminated a contract for 100 million doses, then its only order.

WeaPlay, WordPress Theme, Business Consulting Nulled, Avada 7.4 Nulled, Newspaper – News & WooCommerce WordPress Theme, Nulledfire, Elementor Pro Weadown, Astra Pro Nulled, Plugins, Rank Math Seo Pro Weadown, Woodmart Theme Nulled, Elementor Pro Weadown,Woodmart Theme Nulled, Wordfence Premium Nulled, Flatsome Nulled, Yoast Nulled, Woocommerce Custom Product Ad, Jannah Nulled, Dokan Pro Nulled, Fs Poster Plugin Nulled, Jnews 8.1.0 Nulled, PW WooCommerce Gift Cards Pro Nulled, Newspaper 11.2, Premium Addons for Elementor, Slider Revolution Nulled, Wpml Nulled, PHP Script, WP Reset Pro, Consulting 6.1.4 Nulled

Back to top button